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The resistance to interferons (IFNs) limits their anticancer therapeutic efficacy. Here we studied the evolution of an IFN-resistant
state in vitro using melanoma cell lines. We found that the cells became less sensitive to antiproliferative effect of IFN-g after
prolonged cultivation enabling us to isolate sensitive and resistant subclones of the parental line. We investigated transcription
of signal transducer and activator of transcription (STAT) 1–6 and suppressor of cytokine signalling (SOCS) 1–3 genes, and
phosphorylation of STAT 1 protein. The resistant subline (termed WM 1158R) differed from the sensitive subline (WM 1158S) by a
constitutive expression of SOCS 3, lack or weak SOCS 1–3 activation following IFN-g, and short duration of cytokine activatory
signal. Similar correlations were observed in additional melanoma lines differing in IFN sensitivities. At the protein level, IFN-g induced
strong and prolonged STAT 1 activation at serine 727 (S727) in WM 1158R while in WM 1158S cells phosphorylation of this amino
acid was much less pronounced. On the other hand, phosphorylation of tyrosine 701 (Y701) was stimulated regardless of the
sensitivity phenotype. In conclusion, constitutive expression of SOCS 3 is correlated with attenuation of its induction following IFN
treatment. These results suggest that progression of melanoma cells from IFN sensitivity to IFN insensitivity associates with changes in
SOCS expression.
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It has been well established that interferons (IFNs) can inhibit the
growth and proliferation of a wide variety of tumour cells. Their
action is generally cytostatic rather than cytotoxic, and inhibition
of progression through cell cycle phases has been shown.
Therapeutic utility of IFN administration has been primarily
demonstrated in some leukaemia and from solid type of
malignancies in renal cell carcinoma, Kaposi’s sarcoma and
malignant melanoma –(for review see Lens and Dawes, 2002).
However, the effectiveness of the treatment is often unsatisfactory
probably due to per se resistance of some tumour cell subclones
and/or acquired resistance to IFN biological effects.
Biologic activities of IFNs are mediated upon interaction with
specific cell surface receptors and activation of intracellular
signalling cascades (Ransohoff, 1998). Janus kinase (JAK)/signal
transducer and activator of transcription (STAT) proteins play a
key role in IFN-induced signalling that consequently modulate
essential cellular functions such as growth, differentiation and
apoptosis (Brierley and Fish, 2005). STAT 1 is certainly needed for
transmission of IFN-g signals (Durbin et al, 1996), but the role for
other STATs including STAT 3 (Ramana et al, 2005) is emerging as
well. Recent recognition of JAK/STAT signalling pathways as
inevitable molecular mechanism of various cellular effects of
IFNs has elicited a considerable effort to elucidate the role of
their components in cancer (Calo et al, 2003). In malignant
melanoma, some studies demonstrated reduced STAT 1 activity in
IFN-resistant cell lines pointing to defects in the JAK/STAT
pathways (Wong et al, 1997; Pansky et al, 2000). Alterations
occurred at both protein and RNA levels and at post-translational
phosphorylation modifications. While most melanoma cell lines
displayed normal Y701 phosphorylation response to IFN-g
treatment, phosphorylation block at S727 appeared to be more
frequent (Kovarik et al, 2003). On the other hand, variable STAT 1
levels without apparent correlation with cell sensitivity towards
IFNs were also reported (Chawla-Sarkar et al, 2002; Jackson et al,
2003), and in a clinical study, upregulated STAT 1 phosphorylation
was found at high frequency in patients with poor prognosis
(Boudny et al, 2003). In addition to STAT 1, defects in STAT 5
regulation have recently been shown to contribute to IFN
resistance in melanoma cells (Wellbrock et al, 2005). It seems
that involvement of STAT molecules in oncogenesis may be a
rather complex phenomenon.
The duration of STAT function is tightly controlled by several
families of negative regulators including a family of classical
feedback loop regulators – suppressors of cytokine signalling
(SOCSs). Up to now, eight members of these cytokine-induced
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sfamily have been identified that attenuate or inhibit cytokine
growth factor signal –(for review see Hilton, 1999; Fujimoto and
Naka, 2003). Out of these, SOCS 1 (Alexander et al, 1999) and
SOCS 3 (Ramana et al, 2005) appear to be critical inhibitors of
IFN-g signalling. In tumours, dysfunction of SOCS molecules can
cause hyper-responsiveness to cytokines and growth factors and
could contribute to the development and/or progression of
malignant tumours. For example, silencing of SOCS 1 and/or
SOCS 3 genes by methylation of promoter has been correlated
with the loss of growth control inhibition in lung (Yoshikawa
et al, 2001), pancreatic (Komazaki et al, 2004), breast and ovarian
(Sutherland et al, 2004) carcinomas. Similar epigenetic block
apparently affected SOCS 3 gene expression in lung (He et al, 2003)
and head and neck carcinomas (Weber et al, 2005). These studies
indicated that aberrant silencing could be a cause for constitutive
activation of JAK/STAT pathway in cancer cells. However, other
studies also indicated that malignant cells compared to their
normal counterparts express SOCS genes constitutively (Sakai
et al, 2002; Li et al, 2004; Evans et al, 2007) and forced expression
of SOCS transgene often conferred resistance to IFN. Constitutive
expression can potentially hamper immunotherapy by inactivating
cytokine signals. Clearly, many uncertainties remain on the
function of SOCS in tumourigenesis.
Our previous screening of melanoma cell lines showed that
constitutive expression of SOCS 3 was generally low (Kovarik et al,
2005). Nevertheless, few lines showed relatively high level of SOCS 3
expression at both RNA and protein levels. No attempts were made
to correlate expression levels with IFN sensitivity. We now aimed to
investigate the relationship between IFN sensitivity and expression
of STAT and SOCS genes. To reduce the variability caused by
variation in genetic and cell type background, we have used two
sublines derived from the parental human malignant melanoma
WM 1158 line, differing in the sensitivity towards IFN-g.
MATERIALS AND METHODS
Cell cultures
Melanoma WM 1158, WM 9, WM 39, WM 1552C, 1205 Lu cell lines
(Wistar Institute, Philadelphia, PA, USA) were grown in Dulbec-
co’s modified Eagle’s medium (GIBCO, USA) supplemented with
2gl
 1 of sodium bicarbonate, L-glutamine, insulin, antibiotics and
10% of fetal bovine serum. Cells were cultured in the incubator
with 5% CO2 in humidified atmosphere. Human epidermal
melanocytes (manufacture code C-002-5C) isolated from lightly
pigmented neonatal foreskin were purchased from Cascade
Biologics, USA. The cells were grown in the medium 254
supplemented with human melanocyte growth supplement (both
Cascade Biologics, USA). The cells were obtained at the end of the
secondary culture stage and have passed three to six passages until
used for experiments.
Growth inhibition assay and statistical analyses
Cells were seeded into 96-well microplates at a density of 2000 cells
per well. One day after seeding, the medium was replaced by
medium containing IFN-g (Sigma, Saint Louis, MO, USA) at
concentrations of 50, 100, and 200ngml
 1. After 24, 48 and 72h
intervals of treatment, WST-1 colourimetric assay (Roche,
Mannheim, Germany) was performed according to the manufac-
turer’s protocol. The absorbance was measured in three
parallel wells. The growth inhibition (cytotoxicity) was evaluated
in at least three independent experiments and expressed as the
amount of viable cells in treated and untreated samples (Figure 1A
and B) or as the cell viability normalised to untreated controls
(Figure 1C). The data were statistically analyzed employing a
parametric t-test.
Western blot analyses
The cells were harvested and lysed according to standard
procedures (Boudny et al, 2003). The protein content in whole-
cell extracts was determined by Bradford assay (Bio-Rad, Munich,
Germany). Approximately, 20mg of total proteins were separated
by sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(10% gels) and the proteins were transferred to nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA). Phosphorylated STAT
proteins were visualised after immunoprecipitation as described
in Kovarik et al (2003). After the primary antibody binding
reaction, the blots were incubated with either anti-mouse or anti-
rabbit horseradish peroxidase-conjugated secondary antibody
(Amersham Biosciences, Little Chalfont, Buckinghamshire, UK)
and developed using the enhanced chemiluminiscence detection
system (Amersham) according to manufacturer’s instructions.
For the detection of STAT 1 phosphoforms, commercial STAT 1
anti-pY701 rabbit polyclonal antibody (Cell Signaling Technology,
Danvers, MA, USA) and home-developed anti-pS727 mouse
monoclonal antibody (pSM1, Kovarik et al, 2003) were used. Total
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Figure 1 Antiproliferative effect of IFN-g in WM 1158S and WM 1158R
sublines measured by WST-1 colourimetric test. (A and B) The growth is
expressed as the amount of viable cells in treated and untreated samples.
Each value represents a mean from three independent experiments. Error
bars indicate s.d. (C) The cell viability normalised to untreated controls.
The differences between WM 1158S and WM 1158R sublines were
statistically significant (Po0.01) for all time intervals (24, 48 and 72h).
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sSTAT 1 protein levels were assayed by rabbit polyclonal antiserum
against C-terminal domain of STAT 1 raised in author’s lab (S1C).
RNA analyses
Total RNAs were isolated from cells treated with 50ngml
 1 of
IFN-g for various intervals using RNAeasy kit (Qiagen, Hilden,
Germany). Each sample was extensively treated with DNaseI. The
corresponding cDNAs were prepared by reverse transcription
using Superscript II polymerase (Invitrogen, Carlsbad, CA, USA).
The cDNAs were amplified using a multigene 12-well format strip
(SuperArray, Biosci Co., Frederick, MD, USA) containing sets of
primers for seven STATs, four SOCSs and GAPDH genes. The PCR
was carried out in a MJ Research thermocycler according to the
manufacturer’s recommendation using 30 cycles at a maximum to
keep the reaction in a linear phase. The 5–10ml aliquots were
loaded on a 2% agarose gel. The sizes of bands were estimated
from size markers and found to fit with expected sizes of
amplicons. The ethidium bromide fluorescent signals were
scanned by a CCD camera (Ultralum) and quantified (Ultraquant).
In some cases, the reverse transcriptase (RT)–PCR results were
verified by Northern blot using SOCS 1 (Hebenstreit et al, 2005)
and SOCS 3 (Masuhara et al, 1997) probes as described in Kovarik
et al (2005).
RESULTS
Differential sensitivity of WM 1158 sublines to interferon-c
Upon continuous cultivation of WM 1158 melanoma cells, we
observed gradual decrease of sensitivity towards IFN-g. Repeated
cloning resulted in the isolation of resistant (WM 1158R) and
sensitive (WM 1158S) sublines. While IFN-g retarded the growth
of WM 1158S by 80–90%, the growth of WM 1158R cells was
significantly less inhibited (Figure 1 and Table 1). The growth
properties of both sublines in the absence of IFN-g were similar
(Figure 1A and B) as well as cell morphology (data not shown). The
antiproliferative effect of IFN was further studied in several
additional melanoma lines (Table 1). These cells can be roughly
categorised into high (WM 1158S, WM 39, WM 1552C), medium
(WM 1158R) and low (WM 9, 1205 Lu) sensitive ones. The low
sensitivity of WM 9 line towards IFN-g was in a good agreement
with that previously published (Kortylewski et al, 2004).
Expression profiles before interferon-c treatment
Reverse transcriptase–PCRs were carried out in 12-well strips
allowing simultaneous expression analysis of STAT 1–6, SOCS
1–3 and SOCS 5 genes (Figures 2A–4A, upper panels). As a
reference, each strip contained primers amplifying a constitutively
expressed GAPDH gene. Isolated RNAs were reverse transcribed
and corresponding cDNAs amplified using specific primers. The
first seven lanes in each strip show amplification products
obtained with primers specific for various STATs. Most STATs
were amplified generating strong bands in all cell lines suggesting
their constitutive expression. However, there were differences in
the intensities of individual bands. For example, STAT 4 signal was
weak and even missing (in melanocytes) compared to other
STATs. The STAT 5B band was consistently stronger than that of
STAT 5A.
The SOCS primers were designed to allow detection of SOCS 1,
2, 3, and 5 transcripts. The bands corresponding to SOCS 1, 2, and
3 transcripts were hardly visible in WM 1158S (Figure 2A),
indicating that expression of most SOCSs was low or negligible
before IFN treatment. In contrast, WM 1158R showed relatively
strong SOCS 3 signals (Figure 3A) arguing for a constitutive
Table 1 Relation between cell sensitivity to IFN-g, SOCS 3 mRNA levels and
SOCS 3 inducibility
Line IFN-g resistance
a SOCS 3 constitutive expression
b SOCS 3 induction (fold increase)
c
1205 Lu 90–100 0.7 1.0
WM 9 86–98 0.5 1.3
WM 1158R 68–80 0.4 2.4
WM 39 28–38 0.03 9.5
WM 1552C 39–43 0.03 12.7
WM 1158S 10–20 0.05 7.5
Abbreviations: IFN¼interferon; SOCS¼suppressors of cytokine signalling.
aExpressed as a percentage of viable cells after the 72h time interval of IFN-g treatment as related to
untreated controls. Range of cytotoxicity values from at least three parallel experiments.
bAssayed by RT–PCR as described in Figures 2 and 3. Fluorescent signals were
normalized to GAPDH. Means of at least two independent experiments are shown.
cFold increase over the non-treated control after 30min of IFN-g treatment.
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Figure 2 Analysis of STAT and SOCS transcripts in the sensitive WM
1158S subline. (A) Total RNAs were prepared from cells treated with
IFN-g for 30min, 24 and 72h and from non-treated controls. The
DNA products of RT–PCRs were separated on 2% agarose gels. (B)
Transcription is expressed as a SOCS/GAPDH ratio or (C) fold increase
over basal level. Means of three independent experiments are shown.
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sexpression of SOCS 3 in these cells. To quantify transcript levels,
we measured fluorescence intensities of individual bands and
expressed data as the SOCS 3/GAPDH ratio (Figures 2B–3B and
Table 1). RT–PCR analysis of SOCSs RNA was further carried
out in additional melanoma cell lines (Table 1) and in human
melanocytes (Figure 4). Relatively strong SOCS 3 signals were
observed in both IFN-resistant WM 9 and 1205 Lu lines while low
constitutive expression displayed relatively sensitive WM 39 and
WM 1552C (Table 1) and the melanocytes (Figure 4A). Compared
to SOCS 3, the SOCS 1 signals were barely detectable except of 1205
Lu (data not shown). Abundant SOCS 5 transcripts were detected
in all cell lines (exemplified in Figures 2A–4A).
Expression profiles after IFN-c treatment
After the IFN-g treatment, there were no material changes
in the STAT transcripts profiles. In melanocytes, there was a
moderate (1.5-fold) increase of STAT 1 (Figure 4) while no
increase was observed in melanoma lines (Figures 2–3). However,
IFN-g slightly elevated STAT 5 and STAT 6 signals in melanoma
cells.
Significant qualitative changes occurred in a spectrum of SOCS-
specific bands after the IFN treatment (Figures 2–4). The most
prominent changes involved SOCS 3 and SOCS 1 transcripts. SOCS
3 expression was significantly induced in WM 1158S subline
(Figure 2), WM 1552C and WM 39 cells (Table 1) as well as in
normal melanocytes (Figure 4). However, no or weak SOCS 3
signals were detected in WM 9 and 1205 Lu cells (Table 1) and WM
1158R subline (Figure 3). The induction levels were expressed as a
ratio of normalised signals in IFN-treated and -non-treated cells
(Figures 2C–4C, Table 1). Detailed kinetic analysis (Figures 2–4)
revealed that in both WM 1158S and melanocytes the SOCS 3
signal peaked within 24h following IFN-g treatment while in WM
1158R the faint induction was time-limited and reached its
maximum in a 30min interval. After 72h, there was no apparent
difference between non-treated and treated WM 1158R cells,
whereas WM 1158S still retained elevated SOCS 3 expression.
Intensities of the SOCS 1 bands were generally much lower than
those of SOCS 3. Nevertheless, it is evident that SOCS 1 bands were
visible after IFN-g in both WM 1158S and WM 1158R and
melanocytes. Compared to SOCS 3, the induction was shifted to a
longer exposure time. IFN treatment had no apparent effect on
SOCS 2 RNA levels.
STAT 1 phosphorylation
Several studies indicated the importance of activated (phosphory-
lated) STAT 1 molecules in IFN resistance. We explored STAT 1
phosphorylation status in cell extracts of sensitive and resistant
sublines derived from WM 1158 melanoma cells isolated from
different time intervals of IFN treatment (Figure 5). In the resistant
WM 1158R subline, the signal corresponding to phosphorylated
S727 isoform sharply increased within 30min after the induction
with IFN-g and remained stable thereafter. In contrast, the
sensitive WM 1158S cells showed relatively uniform pS727 bands,
not significantly influenced by IFN treatment. Both sublines
exhibited increased and stable pY701 signals in the presence of
IFN-g. STAT 1 levels were not significantly influenced by IFN
treatment as revealed by staining of blots with an antibody
recognising a primary determinant (Figure 5, bottom panels).
Similar STAT 1 phosphorylation results were also observed in
additional WM 9 and WM 39 melanoma cell lines as well as in
melanocytes (data not shown).
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Figure 3 Analysis of STAT and SOCS transcripts in the resistant WM
1158R subline. The conditions and experimental set-up were as in Figure 2.
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sDISCUSSION
Development of interferon resistance over cell culture
passages
In the present study, we have isolated and characterised
interferon-sensitive and -insensitive sublines of a parental
melanoma line. Development of cytokine resistance is a known
complex phenomenon linked to progression from early to
advanced stages of malignant melanoma (Lu et al, 1993). It could
be a result of selection of pre-existing resistant cells in parental
tumour or alteration of signal transduction pathways as a result
of genetic/epigenetic cellular changes. Our data do not allow to
distinguish between both possibilities. Interestingly, similar switch
towards IFN-g-resistant phenotype was previously reported in
cervical carcinoma cells (Lee et al, 1999), suggesting that
emergence of IFN-resistant phenotype might be a general feature
of cells that have passed multiple divisions in vitro and possibly in
vivo as well. However, while in their experiments the sensitivity
change was correlated with the loss of STAT 1 expression, in our
system STAT 1 continued to be expressed and faithfully
phosphorylated at tyrosine residues at least. Perhaps there might
be multiple alternative pathways influencing antiproliferative
potential of IFNs.
Expression profiles of SOCSs in melanoma cells
The SOCS gene products are known STAT-induced negative
regulators of STATs phosphorylation. We took advantage of the
availability of sensitive and insensitive derivatives of WM 1158
line to study changes in SOCS expression patterns. In this way, we
reduced variation originating from different parental origin
(tumour stage, histological type and patient individuality) of cell
lines. Out of four SOCS genes investigated, SOCS 3 and SOCS 1
appeared to be the best responders while SOCS 2 and SOCS 5 were
insensitive to IFN-g challenge (Figures 2–4). The absence of SOCS
5 induction fits with the current view that SOCS 5 is not a classical
feedback regulator of cytokine signalling (Fujimoto and Naka,
2003). The induction of SOCS 3 transcripts remarkably differed
between the WM 1158 sublines: while the sensitive subline showed
in average 7.5-fold induction of SOCS 3, there was only marginal
transcript increase in its IFN-resistant variant (Table 1). The
differences were less pronounced for SOCS 1, and the induction of
this gene also showed higher level of variation (Figures 2–3). The
kinetic experiments showed that the sensitive subline maintained
elevated SOCS 1 and SOCS 3 mRNA levels for 472h following
IFN-g challenge while both transcripts were attenuated rapidly to
basal levels in the resistant WM 1158R. Significantly, duration of
elevated SOCSs expression correlated with the growth inhibition
that was most pronounced within the 24–72h interval (Figure 1).
These results indicated differences in the extent and dynamics of
SOCS 1 and SOCS 3 IFN-mediated activation between sensitive and
resistant sublines. Interestingly, a good correlation between
constitutive SOCS 3 expression, lack of its inducibility and IFN
cell resistance was obtained in additional melanoma cell lines
(Table 1). The strong upregulation of SOCS 3 following IFN-g
could be a specific feature of melanoma lineages because epithelial
breast cancer cells showed its downregulation (Evans et al, 2007)
or variable expression (Souckova, unpublished data). However, in
breast cancer cells SOCS 1 was strongly activated while its
induction was rather weak in melanoma lines used. It is likely
that SOCS activation pathways operate differently in diverse cell
and tissue types.
In general, the cell sensitivity to interferon was better correlated
with inducibility of SOCS 3 than that of SOCS 1. The question
arises as to the possible cause of differential activation of these
genes. Epigenetic changes in the course of prolonged cultivation of
cells have been well described (Chow and Rubin, 2000; Fojtova
et al, 2003) and both SOCS genes were shown to be inactivated
by methylation of their promoters (He et al, 2003). However, we
consider this possibility unlikely since the IFN-insensitive WM
1158R subline expressed SOCS 3, suggesting that the promoter is
transcriptionally active. Although highly specific methylation of an
IFN–responsive element in the promoter cannot be entirely
excluded, we favour the hypothesis that constitutive SOCS 3
expression could counteract the transactivatory signals delivered
by IFN-activated STATs. In support, three IFN-insensitive WM
1158R, WM 9 and 1205 Lu melanoma lines had high basal
expression of SOCS 3 compared to sensitive cells. Furthermore,
breast cancer (Evans et al, 2007) and leukaemia cells (Sakai et al,
2002) showed elevated constitutive expression of SOCS 1 and SOCS
3 and the resistance to proinflammatory cytokines including
IFN-g. Perhaps IFN sensitivity of a SOCS 3 promoter is reduced
due to aberrant expression of an activatory transcription factor(s).
In this context, aberrant activation of tissue-specific promoters has
been observed in cancers (Kovarik et al, 1993).
Relation between SOCSs induction and STAT 1
phosphorylation
Since STAT 1 is one of the major targets of phosphorylation
elicited by IFN-g, we have investigated relationship between STAT
1 phosphorylation at S727 and Y701 residues and SOCS induction.
Our semi-quantitative RT–PCR failed to reveal significant
differences in STAT 1 levels (both constitutive and induced),
suggesting that amounts of gene products were not markedly
influenced by IFN (Lesinski et al, 2005). At the protein
modification level, IFN-g stimulated phosphorylation of Y701
residues in both sensitive and insensitive cells consistent with
previous studies that demonstrated lack or weak correlation
between Y701 STAT 1 phosphorylation and cell sensitivity to
cytokine stimuli (Chawla-Sarkar et al, 2002; Kortylewski et al,
2004). Surprisingly, the differences in IFN sensitivity were best
reflected by the second most commonly phosphorylated site, the
S727 residue: while the IFN-sensitive WM 1158S cells did not show
marked increase of S727 phosphorylation following IFN-g treat-
ment, there was extensive and prolonged phosphorylation of this
amino acid in the insensitive subline. Considering that SOCS 3
regulator was more strongly activated in the IFN-sensitive subline,
it is tempting to speculate that phosphorylation of S727 residues
was specifically blocked by this molecule. In this context, S727-
phosphorylated STAT 1 provided apoptotic resistance for Wilms
tumour cells (Timofeeva et al, 2006). Although phosphorylation at
Y701 was shown to be sufficient for transactivatory capacity of
STAT 1 molecule (Shuai et al, 1993), S727 phosphorylation seems
to be an important modulator of target specificity in haemopoetic
cells (Kovarik et al, 2001). Perhaps high levels of STAT 1
phosphorylation at S727 might activate specific genes involved in
IFN resistance.
WM 1158R
C 0.5 h 24 h 48 h 72 h C 0.5 h 24 h 48 h 72 h
pS727 STAT1
pY701 STAT1
S1C STAT1
WM 1158S
Figure 5 STAT 1 phosphorylation levels in both IFN-resistant and IFN-
sensitive WM 1158 sublines. The proteins were extracted from the same
cellular pool as used for RNA analysis and analysed by Western blot. All
experiments were performed in triplicates.
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In normal human melanocytes, SOCS 3 appeared to be strongly
induced following IFN-g while its basal levels were low or
negligible. The induction was quite stable and only marginal
decrease occurred within the 72h treatment interval. In this aspect,
there were apparent similarities between normal cells and the
IFN-sensitive WM 1158S melanoma subline. However, melano-
cytes differed from malignant cells in no or marginal SOCS 1
expression. This is congruent with another study showing low
levels of SOCS 1 in melanocytes compared to melanoma cell lines
(Li et al, 2004). However, in their study the lack of SOCS 1
expression occurred at the protein but not at the RNA level. Our
failure to detect SOCS 1 in melanocytes might be explained by
differences in the sensitivity of the RT–PCR assay (e.g., variable
number of cycles), and perhaps by other factors.
Conclusions and further directions
In conclusion, prolonged maintenance of melanoma cells in cell
culture may lead to reduction of their sensitivity to IFN-g. At the
molecular level, this process is associated with increased
constitutive expression of SOCS 3 whose levels are no longer or
marginally influenced by IFN signals. Our data suggest that
changes in the SOCS 3 expression are tightly bound with the
progression of melanoma cells from IFN-sensitive to IFN-resistant
phenotype and may account for a growth advantage of melanoma
in vivo at its advanced stages. In the future, it will be interesting
to analyse the expression of various SOCSs in clinical samples to
correlate their expression profiles with patients’ responsiveness to
IFN-based immunotherapy and disease outcome.
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